Stock Research: SK Biopharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

SK Biopharmaceuticals

KOSE:A326030 KR7326030004
8
  • Value
    14
  • Growth
    74
  • Safety
    Safety
    4
  • Combined
    10
  • Sentiment
    55
  • 360° View
    360° View
    8
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

SK Biopharmaceuticals Co Ltd is a Korea-based pharmaceutical company focused on the development and manufacture of drugs. The company operates in the pharmaceutical industry, developing and producing epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, bipolar disorder drugs, and new drug development. The company is based in Korea. In the last fiscal year, the company had a market cap of $5509 millions, profits of $342 millions, and revenue of $371 millions.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 8 (better than 8% compared with alternatives), overall professional sentiment and financial characteristics for the stock SK Biopharmaceuticals are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for SK Biopharmaceuticals. The consolidated Growth Rank has a good rank of 74, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 74% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 55, which means that professional investors are more optimistic about the stock than for 55% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 4, which means that the share price of SK Biopharmaceuticals is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 96% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 14, which means that the company has a financing structure that is riskier than those of 86% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
KOSPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
4 1 1 1
Growth
74 82 100 93
Safety
Safety
14 4 6 22
Sentiment
55 88 59 52
360° View
360° View
8 35 27 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
64 60 63 59
Opinions Change
45 50 55 50
Pro Holdings
n/a 78 30 22
Market Pulse
77 82 84 70
Sentiment
55 88 59 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
4 1 1 1
Growth
74 82 100 93
Safety Safety
14 4 6 22
Combined
10 7 16 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
11 7 1 1
Price vs. Earnings (P/E)
5 5 1 3
Price vs. Book (P/B)
3 1 1 3
Dividend Yield
1 1 1 1
Value
4 1 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
100 98 98 81
Profit Growth
11 6 81 88
Capital Growth
80 60 73 91
Stock Returns
44 88 85 9
Growth
74 82 100 93
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
31 19 19 70
Refinancing
14 6 15 11
Liquidity
37 10 6 1
Safety Safety
14 4 6 22

Similar Stocks

Discover high‑ranked alternatives to SK Biopharmaceuticals and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Korea Investment

KOSE:A071050
Country: South Korea
Industry: Investment Banking & Brokerage
Size: Large
Full Stock Analysis

Kia Motors

KOSE:A000270
Country: South Korea
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.